[Angiogenesis inhibitors and radiotherapy]

O Riesterer1

  • 1Klinik und Poliklinik für Radio-Onkologie, Universitätsspital Zürich. oliver.riesterer@usz.ch

Praxis
|August 11, 2012
PubMed

Insights

Angiogenesis inhibitors (AI) combined with radiotherapy show promise for cancer treatment. Preclinical data suggest AI can normalize tumor vasculature, potentially overcoming radio-resistance and improving outcomes.

Area of Science:

  • Oncology
  • Vascular Biology
  • Radiation Oncology

Context:

  • Tumor angiogenesis is a key therapeutic target in cancer treatment.
  • Combining angiogenesis inhibitors (AI) with radiotherapy presents a novel strategy.
  • Clinical application has been limited by concerns of increased tumor hypoxia and radio-resistance.

Purpose:

  • To explore the biological interactions between angiogenesis inhibitors and radiotherapy.
  • To evaluate the potential of AI in overcoming radio-resistance and improving treatment outcomes.
  • To provide a rationale for ongoing and future clinical studies.

Summary:

  • Angiogenesis inhibitors (AI) target tumor vasculature, while radiotherapy affects both tumor cells and vasculature.
  • Preclinical studies indicate AI can induce vascular normalization, counteracting the initial concern of increased hypoxia.
  • Consolidation therapy with AI post-radiotherapy is a promising approach due to the specific biology of irradiated tumor beds.

Impact:

  • This research supports the increasing clinical investigation of combined AI and radiotherapy strategies.
  • Findings may lead to improved cancer treatment protocols by optimizing the use of angiogenesis inhibitors and radiation.
  • Understanding the interplay between AI and radiation biology can enhance therapeutic efficacy and patient outcomes.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...